InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 10.84
+0.49 (4.73%)
Jun 18, 2026, 4:08 PM HKT
InnoCare Pharma Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, InnoCare Pharma stock has a consensus rating of "Strong Buy" and an average price target of $19.66. The average 1-year stock price forecast is 81.37% higher than the current stock price, while the lowest is $17.03 (+57.10%) and the highest is $22.37 (+106.37%).
Price Target: $19.66 (+81.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for InnoCare Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 9 | 9 | 10 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 10 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Upgrades $19.60 → $17.00 | Buy | Upgrades | $19.60 → $17.00 | +56.83% | May 28, 2026 |
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $19.40 | Buy | Maintains | $19.40 | +78.97% | May 14, 2026 |
| CMB International Securities | CMB International Securities | Buy Maintains $11.95 → $18.31 | Buy | Maintains | $11.95 → $18.31 | +68.91% | Apr 24, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $19.80 → $21.40 | Buy | Maintains | $19.80 → $21.40 | +97.42% | Apr 23, 2026 |
Unknown Analyst Guoyuan Securities (HK) No rating | Guoyuan Securities (HK) | Buy Maintains $16.81 | Buy | Maintains | $16.81 | +55.07% | Dec 25, 2025 |
Financial Forecast
Revenue This Year
2.34B
from 2.37B
Decreased by -1.68%
Revenue Next Year
2.87B
from 2.34B
Increased by 22.80%
EPS This Year
0.11
from 0.39
Decreased by -73.38%
EPS Next Year
0.10
from 0.11
Decreased by -4.76%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.6B | ||
| Avg | 2.3B | ||
| Low | 2.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.1% | ||
| Avg | -1.7% | ||
| Low | -12.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.11 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -73.4% | ||
| Low | - |